

# **Viruses and Human Cancer**

**Robin A Weiss**

**Division of Infection & Immunity**

**University College London**

**Viruses: The Invisible Enemy**

**Venice, 21 September 2010**



# **Overview**

**1842: Domenico Rigoni-Stern, Verona: no cervical cancer in nuns**

**Oncogenic viruses in animals were discovered 100 years ago**

**The first oncogenic human virus (EBV) was discovered in 1964**

**Oncogenic viruses have taught us much about cancer:**

**Tumor suppressor p53 first discovered in association with PyV**

**Oncogenes were first defined in retroviruses**

**Approximately 15% of human cancer worldwide has a viral etiology**

**Vaccines against these viruses will significantly reduce the human cancer burden**

## Human cancers attributable to infection


Agent	Cancer	% lifetime risk in carriers	Annual cases	% all cancers	Main transmission route
<i>H. pylori</i>	Stomach Lymphoma (MALT)	~10.0	592,000 11,500	5.8	Oral
HPV	Cervix (HPV-16, 18)	~3.0	492,800	5.1	Sexual
	Ano-genital		53,880	0.5	
	Mouth, pharynx		14,500	0.1	
	Skin (HPV-5)	<0.01	~1,000	<0.01	Contact
HBV and HCV	Liver	~15.0	535,000	5.5	Parenteral
EBV	Nasopharynx	<1.0	78,100	1.0	Oral
	Hodgkin lymphoma		28,600	0.3	
	Burkitt lymphoma		6,700	0.06	
KSHV (HHV-8)	Kaposi sarcoma	<1.0	66,200	0.9	Oral
	NHL		16,100		
Schistosome	Bladder	<1.0	10,600	0.1	Water, snails
HTLV-1	ATL	~1.2	3,300	0.03	Milk
Opisthorchis	Gall bladder	~5.6	2,500	0.02	Water, raw fish
Merkel PyV	Skin	<0.01	~1,500	<0.01	Contact

(Adapted from Parkin, 2006)

# Annual global cancer burden due to infections

**2,216,920 new cases = 20.6% of total cancer incidence**

(adapted from Parkin et al. 2002, 2006)



This pie chart excludes the remaining 3.6%:

- Anal and perianal cancers (HPV)
- Vulvar, vaginal and penile cancers (HPV)
- Adult T cell leukemia (HTLV-1)
- Kaposi sarcoma and KSHV lymphomas
- Merkel cell carcinoma (MCPyV)
- MALT tumours (*H. pylori*)
- Cancers linked to helminth infections

>99% cancer of the cervix (HPV)

25% cancers of the oral cavity (HPV)

80% hepatocellular carcinoma  
(HBV 50%, HCV 30%)

80% gastric cancer (*H. pylori*)

10% gastric cancer (EBV)

>99% undifferentiated  
nasopharyngeal carcinoma (EBV)

10% non-Hodgkin lymphoma (EBV)

30% Hodgkin lymphoma (EBV)

## **Paradox: oncogenic viruses that don't cause human cancer**

**Adenoviruses: AdV 2, 5 & 12**

**Highly oncogenic in new born rats due to  
E1A, E1B, E4 & E5**



**Polyomaviruses: BKV, JCV**

**Highly oncogenic in baby hamsters due to large T  
and small t antigen transformation**

**HTLV-2: Immortalizes T-cells in culture**

# Merkel Cell Carcinoma

- Rare, aggressive skin cancer
- Occurs in the elderly
- Transplant recipients and AIDS
- New polyoma virus discovered 2008




**Feng, Shuda, Chang & Moore (2008)**  
**Clonal integration of a PyV in**  
**human Merkel cell carcinoma.**  
***Science* 319: 1096–1100.**



# Merkel cell carcinoma virus is phylogenetically distant from other human polyoma viruses

Large T antigen (T-1)



## **Distinguishing tumor viruses from rumor viruses**

<b>1972-1974</b>	<b>RD114</b>	<b>Pediatric sarcoma</b>	<b>Feline gamma-retrovirus</b>
<b>1972-present</b>	<b>MMTV</b>	<b>Breast cancer</b>	<b>Murine beta-retrovirus</b>
<b>1992-2004</b>	<b>SV40</b>	<b>Various</b>	<b>Simian polyomavirus</b>
<b>2006-2010</b>	<b>XMRV</b>	<b>Prostate cancer</b>	<b>Murine gamma-retrovirus</b>

**Rnase L mutation?**

**XMRV in stroma, carcinoma or neither?**



## Distinguishing tumor viruses from rumor viruses

1972-1974	RD114	Pediatric sarcoma	Feline gamma-retrovirus
1972-present	MMTV	Breast cancer	Murine beta-retrovirus
1992-2004	SV40	Various	Simian polyomavirus
2006-2010	XMRV	Prostate cancer	Murine gamma-retrovirus

Rnase L mutation?

XMRV in stroma, carcinoma or neither?

## Rumors about genuine tumor viruses: KSHV (HHV-8)

1994	Kaposi sarcoma	True
1995	Primary effusion lymphoma	True
1996	Multicentric Castleman's disease	True
	(PCR, Southern blot, Ag, isolation, serology)	
1996	Multiple myeloma (PCR)	False
1997	Sarcoidosis (PCR)	False

## **Multifactorial causes of cancer**

**(virus is necessary but not sufficient to cause cancer)**

### **1. Liver cancer (HCC)**


- **HBV alone: medium frequency of HCC**
- **Aflatoxin in diet: HCC rare**
- **HBV + aflatoxin: ~5-fold relative risk in HCC**  
**(Wild & Montesano 2009)**

### **2. Skin cancer in EV**

- **HPV-5, HPV-8 (ubiquitous)**
- **Ultraviolet light exposure (on face)**
- **Epidermodysplasia verruciformis gene (rare)**

# Multifactorial causes of cancer

## 3. Burkitt's Lymphoma in children




**Epstein-Barr Virus (EBV)**

**Holoendemic malaria**

***C-myc* translocation to Ig heavy or light chains 8;14, 8;2 or 8;22**



# Multifactorial causes of cancer

## 4. Kaposi's sarcoma (KS)



- 1<sup>o</sup> cause: KSHV (HHV-8)
- Classical:  
rare, in elderly men
- Iatrogenic: commoner in immunosuppressed transplant patients
- AIDS-KS, role of HIV:  
immunosuppression + Tat?

# Oncogenic viruses and changes in cancer incidence when AIDS appeared







## **Humankind's Collection of Viruses**

### **Family Heirlooms (co-evolved with host)**

**Endogenous Retroviruses**

**Herpesviruses**

**Papilloma & polyoma viruses**

**Hepatitis B virus**

### **Temporary Exhibits (zoonoses, outbreaks)**

**Rabies**

**West Nile**

**Nipah**

**Ebola**

**SARS**

### **'New' Acquisitions (<12,000 years ago)**

**Measles**

**Smallpox**


**Influenza**

**HIV**

(Weiss RA & McMichael AJ, Social and environmental risk factors in the emergence of infectious diseases. *Nature Med* 10, S70, 2004)

## KSHV is a Maternal Heirloom


- In Africa, 98% KSHV-infected children have KSHV+ mothers but there is no correlation with infection status of fathers (Bourboulia *et al*, 1998; Dedicoat *et al*, 2004; Plancoulaine *et al*, 2004)





# KSHV is a Maternal Heirloom

- In Africa, 98% KSHV-infected children have KSHV+ mothers but there is no correlation with infection status of fathers (Bourboulia *et al*, 1998; Dedicoat *et al*, 2004; Plancoulaine *et al*, 2004)
- In Ashkenazi Jews, KSHV genomes co-diversify with mtDNA, but not with Y-DNA (Wilder, Weiss & Boshoff, unpublished)



**How long has KSHV been  
present in the Veneto and  
the Po valley?**

**Marcello Fogolino**

**Madonna with San  
Gottardo and San Giobbe**

**1508  
Mantova**



# **Virus: the invisible enemy or the invisible friend**

## **Could viruses be useful to their hosts?**

### **Non-pathogenic:**

**TTV**

**GBV-C co-infection delays progression to AIDS**

**HERV-W in the placental syncytiotrophoblast**

### **Low pathogenic:**

**γ-Herpesviruses**

**KSHV & EBV?**

**Retrovirus**

**HTLV-1 & HTLV-2?**

**KSHV: Loss of fitness to host is a rare side effect usually occurring after reproductive age**


**Its minor cost in fitness might be offset by a broad advantage to the host in a certain environment**

**Analogous to the cost of homozygous lethal genes being outweighed by heterozygous fitness**

# Interactions between infections: Malaria

## Burkitt's Lymphoma


EBV is ubiquitous but BL only occurs where there is malaria



**Detrimental**

## Kaposi's Sarcoma

KSHV prevalence (before AIDS) broadly correlates with malaria



**Beneficial?**



## KSHV and Malaria: Hypotheses

KSHV transmission is enhanced by mosquitos (Ascoli and Coluzzi, 2004)

KSHV might protect against cerebral malaria through secretion of v-MIPs that bind to CCR3 at the blood brain barrier

KSHV is not an 'emerging infection' but has been maintained in the human population by positive selection analogous to genetic hemoglobinopathies




>10% KSHV Ab+

$\beta$ -thalassemia

merged

## **Vaccination against tumor virus infection**

- **HBV SAg recombinant subunit vaccine since 1986:  
Protects against hepatitis and against liver cancer**
- **HPV virus-like particle capsid vaccine:  
Two successful vaccines licensed 2006**
- **EBV Gp340 envelope glycoprotein:  
Not taken up by Pharma Cos**
- **HTLV-1 envelope glycoprotein protects macaques  
and rabbits from challenge:  
Not seen by Pharma Cos as a market**
- **HCV and HIV: Huge markets but no really efficacious  
vaccines yet**



## Conclusions

- **Oncogenic viruses have given us deep insight into cancer eg, oncogenes, tumour suppressor genes**
- **Cancer is a 'side effect' of persistent virus infections that promote cell proliferation**
- **Low penetrance of viral oncogenesis: requires cofactors**
- **Immune deficiencies increase incidence of virus-linked cancers**
- **~ 15% of global human cancer burden has a viral etiology, ~1.6 million cases annually**
- **Vaccines hold great promise to reduce that burden**



**BILL & MELINDA**  
*GATES foundation*

